
European Economic Area
EPA posted a trifludimoxazin registration decision on 30 June 2026 covering one technical and five end-use products. The substance had previously been registered in 2021.
2 min readAI-drafted, expert reviewed

The US Environmental Protection Agency (EPA) posted a final registration decision for trifludimoxazin on 30 June 2026. The decision covers one technical product and five end-use products, including two combinations with saflufenacil.
Trifludimoxazin had previously been registered on 17 May 2021 before those registrations were voluntarily withdrawn. The 2022 application was a new application, rather than the first application for the molecule.
The decision covers specified crop groups, including cereal grains and associated forage, fodder and straw groups excluding rice, alongside maize, soybeans, peanuts, citrus, pome fruit, tree nuts and legume vegetables. Permitted uses remain subject to product-specific labels.
EPA’s decision under section 3(c)(5) of the Federal Insecticide, Fungicide, and Rodenticide Act found no dietary or aggregate human-health risks of concern for the assessed uses. It separately identified ecological risks and mitigation requirements, including controls addressing spray drift and runoff.
Existing residue tolerances remained in place; the application did not include a new tolerance petition. The decision describes condition-dependent degradation of the parent substance and its residues.
Minnesota’s regulatory review, posted on 31 August 2026, explicitly classifies trifludimoxazin as PFAS under Minnesota law. That state classification is separate from EPA’s use-specific federal pesticide registration decision.
The federal docket records when the final memorandum was posted. It does not establish that every individual product registration letter was issued on the same date.
Trifludimoxazin is a fluorinated herbicide active ingredient used to control broadleaf and grass weeds. US pesticide authorisation applies to the uses and conditions specified by EPA.
No. PFAS definitions differ between regulatory and scientific frameworks. Whether trifludimoxazin falls within a particular definition depends on that definition's criteria; the label does not determine every legal obligation.

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanForesight follows changes like this one and shows where they reach your substances, products and markets.
Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at